⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Summit Therapeutics Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Summit Therapeutics Inc.
↗Miami, USA
Summit Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver-, and societal-friendly medicinal therapies. The company aims to improve quality of life and resolve serious unmet medical needs, with a primary focus on oncology.
Its lead development candidate is ivonescimab (SMT112), a novel bispecific antibody that combines PD-1 blockade with anti-angiogenesis. The company is actively conducting multiple Phase III clinical trials for ivonescimab in various indications, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), often in combination with chemotherapy.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Founded:2003
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:SMMT
Market Cap:$10.9B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Bispecific antibody
Trial Phases:Phase 3: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Akeso Inc. (Collaboration for ivonescimab)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Robert W. Duggan - Co-CEO & Executive Chairman
Mahkam Zanganeh - Co-CEO, President & Director
Manmeet Singh Soni - COO, CFO & Director
Scientific Founders:Kay Elizabeth Davies
LINKS
Website:smmttx.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Summit Therapeutics Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.